Proteomic changes upon treatment with semaglutide in individuals with obesity
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 ( n = 1,311) and STEP 2 ( n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways. Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA 1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering. A comparison of semaglutide with real-world proteomic profiles revealed potential benefits on disease-specific proteomic signatures including the downregulation of specific proteins associated with cardiovascular disease risk, supporting its reported effects of lowering cardiovascular disease risk and potential drug repurposing opportunities. This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities. These data also highlight the unmet need for, and importance of, examining proteomic changes in response to weight loss pharmacotherapy in future trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Extended Data Fig. 2 Pathways implicated by proteins affected by semaglutide treatment in STEP 1 (a) and STEP 2 (b). The figure shows the effect of semaglutide treatment (according to SomaScan®) on hallmark gene sets. Circle sizes visually indicate the number of proteins in a set (log2-scale). Black diamonds within the coloured circles indicate sets that are significantly affected by treatment (false discovery rate-adjusted P value [q value] < 0.05). Enrichment P values were computed using CameraPR. Results for the full list of gene sets are available in Supplementary Tables 9 and 10 for STEP 1 and STEP 2, respectively. KRAS, Kirsten rat sarcoma virus; MTORC1, mammalian target of rapamycin complex 1; MYC, myelocytomatosis oncogene.](https://figures.cochat.ai/paper-figures/78524e5e90914fd492d3802451e7b81a/proteomic-changes-upon-treatment-with-semaglutide-in-individuals-with-obesity-figure-7.jpg)
![Extended Data Fig. 3 Proteins increased by semaglutide treatment are implicated in the exocrine pancreas. Effect size was normalized using the means and standard deviations at baseline to compare results across proteins, with positive and negative values indicating that semaglutide increased and decreased protein levels; −log10(P values) indicate the level of significance of the effect size (approximately 500 proteins [approximately 8–10% of the measured proteome] were significant). The red dashed line shows the Bonferroni correction limit, and the blue dashed line shows the false discovery rate. Effect sizes and P values were computed using linear regression. AMY2A/2B, alpha-amylase 2 A/2B; CLPS, caseinolytic protease subunit S; CPB1, carboxypeptidase B1; EOT, end of treatment; PNLIPRP1/2, pancreatic lipase-related protein 1/2; PNLIP, pancreatic lipase; PRSS1/2/3, trypsin 1/2/3.](https://figures.cochat.ai/paper-figures/897c46915b344e819afb65bbca9a1055/proteomic-changes-upon-treatment-with-semaglutide-in-individuals-with-obesity-figure-8.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Proteomic analyses from the STEP weight loss trials in people with or without T2D revealed semaglutide-induced changes in inflammatory and immune regulatory pathways that could not be fully attributed to metabolic improvements alone (25).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence from clinical trials suggests that GLP-1 medicines exert clinical benefits even in individuals who do not experience substantial weight loss (25).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Several GLP-1RAs, including semaglutide, have been shown to offer cardiovascular outcome benefit in people with T2D 33–35 .”
Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 4×
“A total of 3,171 male and female participants were included in the STEP 1 and STEP 2 trials; please refer to the published papers for full details 20,21 .”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 4×
“These benefits are now also evident in people with obesity at high CVD risk (or with known vascular disease) but without T2D, as shown by the favorable effects of semaglutide in the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) clinical trial 36 .”
InfluentialGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“Several GLP-1RAs, including semaglutide, have been shown to offer cardiovascular outcome benefit in people with T2D 33–35 .”
MINIMUM REDUNDANCY FEATURE SELECTION FROM MICROARRAY GENE EXPRESSION DATA
DING, C., & PENG, H. (2005) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720005001004 · Cited by 2,751
(2012) · Hepatogastroenterology · doi:10.5754/hge12458 · Cited by 1,977
Cited by
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
Obesity, diabetes, and inflammation: Pathophysiology and clinical implications
Donath, M. Y., & Drucker, D. J. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.011 · Cited by 69
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“…therapy with either 2 mg exenatide once weekly in the EXSCEL trial 48 , or with 2.4 mg QW semaglutide in the STEP-1 and STEP-2 weight loss trials 49 , revealed reductions in circulating biomarkers of inflammation that also serve as indirect proxies for neuroinflammation in people with…”
InfluentialAdvances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 46
“In a recent 2025 study using large-scale proteomic analysis of serum samples from two phase 3 clinical trials, Maretty et al. demonstrated that semaglutide modulates the circulating proteome in individuals with overweight or obesity, with or without diabetes [67].”
InfluentialGlucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 47
“20 From a mechanistic perspective, however, most evidence regarding the putative neuroprotective activity of GLP-1RAs stems from preclinical, that is, in vitro or animal models.”
Influential
Metadata
- Authors
- Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., Purnell, J. Q., Knudsen, L. B., Tahrani, A. A., & Geybels, M.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Imperial College London (GB)
- Hasselt University (BE)
- Oregon Health & Science University (US)
- Corresponding author
- Tahrani, Abd A.
- ORCID
- Venue
- Nature Medicine
- Published
- 2025-01
- Volume
- 31
- Issue
- 1
- Pages
- 267-277
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11750704
- OpenAlex
- W4406051813
- Cited by
- 86
- References
- 69
- Citations by year
- 2026: 52 · 2025: 33
- FWCI
- 47.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 2 d)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- Document Server@UHasselt (UHasselt) (submittedVersion, other-oa)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, obesity, type 2 diabetes, circulating proteome, serum proteins, pharmacological weight loss, glycemic control, lipid metabolism, inflammation, cardiovascular risk, drug repurposing
- MeSH terms
- Semaglutide, Adult, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Proteome, Proteomics, Glucagon-Like Peptide 1, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteomic changes upon treatment with semaglutide in individuals with obesity. https://app.cochat.ai/papers/10.1038/s41591-024-03355-2
- The paper
- Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., Purnell, J. Q., Knudsen, L. B., Tahrani, A. A., & Geybels, M. (2025). Proteomic changes upon treatment with semaglutide in individuals with obesity. Nature Medicine. https://doi.org/10.1038/s41591-024-03355-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.